Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
In Chinese patients with type 2 diabetes inadequately controlled on metformin, the glucose-lowering effect of cofrogliptin (Q2W) was non-inferior to linagliptin (daily), with a similar safety profile maintained over 52 weeks of treatment.
Authors
- Linong Ji (ORCID: https://orcid.org/0000-0002-3262-2168)
- Qian Ren (ORCID: https://orcid.org/0000-0001-5729-8264)
- Guijun Qin (ORCID: https://orcid.org/0000-0002-2503-7534)
- Ling Li (ORCID: https://orcid.org/0000-0002-1940-8693)
- Junmin Wang (ORCID: https://orcid.org/0000-0001-9830-0164)
- Yü Liu (ORCID: https://orcid.org/0000-0003-2211-3535)
- Jie Han
- Xiaolin Hu (ORCID: https://orcid.org/0009-0000-4896-4595)
- Xiuhai Su
Institutions
- Peking University (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Jinan Central Hospital (CN)
- Peking University People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Nanjing Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1111/dom.15915
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07